Decompensated Cardiac Failure — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for decompensated cardiac failure. 4 active patents protecting 1 drugs from 1+ originators. First major cliff: 2034. Daily refresh.

1
Approved drugs
4
Active US patents
66/100
Avg vulnerability
—
Annual revenue covered

Originators in Decompensated Cardiac Failure

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Generic (originally Hoechst AG) 4 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating decompensated cardiac failure. Each bar = one year. Y-axis scaled to peak year (4 patents).

4
34

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Lasix
furosemide
 Generic (originally Hoechst AG) 4 66 — 2034-04-03

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12370168 Lasix method of use 75 2034-04-03
11433044 Lasix method of use 70 2034-04-03
9884039 Lasix method of use 70 2034-04-03
10272064 Lasix formulation 50 2034-04-03

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10272064 Lasix formulation 50 2034-04-03
11433044 Lasix method of use 70 2034-04-03
9884039 Lasix method of use 70 2034-04-03
12370168 Lasix method of use 75 2034-04-03

Related